1Benson K, Fields K, Hiemenz J, et al. The platelet refractory bone marrow transplant patient Prophylaxis and treatment of bleeding. Semin Oneol, 1993,20 : 102-106.
5Doughty HA, Murphy MF,Metcalfe P,et al. Relative importence of immune and non2immune cause of platelet refractoriness. Vox Sang, 1994,66 ( 2 ) : 200 -205.
6Novotny VMJ . Prevention and Management of Platelet Transfusion Refractoriness. Vox Sang, 1999,76 ( 1 ) : 12-13.
8Hogge D E. Lymphocytotoxic antibody is a predictor of response to random doner platelet treasfusion. Am J Hematol 1983.14. 363-366.
9Benson K, Fields K, Hiemenz J, et al. The platelet refractory bone marrow transoplant patient; prophylaxis and treatment of bleeding. Semin Oncon, 1993,20:102-106.
10Murphy M F, Metcalfe P, Thomas H, et al. Use of leukocyte poor blood components and HLA match platelet donors to prevent HLA alloimmunization. Br JHematol, 1986,62 : 529 - 534.
5Cui Y, Hei F, Long C, et al. Perioperative monitoring of thromboelastograph on hemostasis and therapy for cyanotic infants undergoing complex cardiac surgery. Artif Organs, 2009,33 ( 11 ) : 909- 914.
6Roeloffzen WW, Kluin-Nelemans HC, Veeger N J, et al. Transfused stored platelets have the same haemostatic function as circulating native platelets. Vox Sang,2010,99 (2) : 123-130.
7Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg,2008,106(5) :1366-1375.
8Hett DA, Walker D, Pilkington SN, et al. Sonoclot analysis. Br J Anaesth, 1995,75 (6) :771-776.
